IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination : A Northern Ireland observational study
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: This study evaluates spike protein IgG antibody response following Oxford-AstraZeneca COVID-19 vaccination using the AbC-19™ lateral flow device.
METHODS: Plasma samples were collected from n = 111 individuals from Northern Ireland. The majority were >50 years old and/or clinically vulnerable. Samples were taken at five timepoints from pre-vaccination until 6-months post-first dose.
RESULTS: 20.3% of participants had detectable IgG responses pre-vaccination, indicating prior COVID-19. Antibodies were detected in 86.9% of participants three weeks after the first vaccine dose, falling to 74.7% immediately prior to the second dose, and rising to 99% three weeks post-second vaccine. At 6-months post-first dose, this decreased to 90.5%. At all timepoints, previously infected participants had significantly higher antibody levels than those not previously infected.
CONCLUSION: This study demonstrates that strong anti-spike protein antibody responses are evoked in almost all individuals that receive two doses of Oxford-AstraZeneca vaccine, and which largely persist beyond six months after first vaccination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Vaccine - 40(2022), 18 vom: 20. Apr., Seite 2535-2539 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Robertson, Louise J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.04.2022 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2022.02.087 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338766782 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338766782 | ||
| 003 | DE-627 | ||
| 005 | 20231226001416.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2022.02.087 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1129.xml |
| 035 | |a (DE-627)NLM338766782 | ||
| 035 | |a (NLM)35346536 | ||
| 035 | |a (PII)S0264-410X(22)00262-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Robertson, Louise J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination |b A Northern Ireland observational study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: This study evaluates spike protein IgG antibody response following Oxford-AstraZeneca COVID-19 vaccination using the AbC-19™ lateral flow device | ||
| 520 | |a METHODS: Plasma samples were collected from n = 111 individuals from Northern Ireland. The majority were >50 years old and/or clinically vulnerable. Samples were taken at five timepoints from pre-vaccination until 6-months post-first dose | ||
| 520 | |a RESULTS: 20.3% of participants had detectable IgG responses pre-vaccination, indicating prior COVID-19. Antibodies were detected in 86.9% of participants three weeks after the first vaccine dose, falling to 74.7% immediately prior to the second dose, and rising to 99% three weeks post-second vaccine. At 6-months post-first dose, this decreased to 90.5%. At all timepoints, previously infected participants had significantly higher antibody levels than those not previously infected | ||
| 520 | |a CONCLUSION: This study demonstrates that strong anti-spike protein antibody responses are evoked in almost all individuals that receive two doses of Oxford-AstraZeneca vaccine, and which largely persist beyond six months after first vaccination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adenovirus vector-based vaccine | |
| 650 | 4 | |a Antibody response | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 vaccination | |
| 650 | 4 | |a Oxford-AstraZeneca ChAdOx1 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Price, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Julie S |e verfasserin |4 aut | |
| 700 | 1 | |a Curry, Grace |e verfasserin |4 aut | |
| 700 | 1 | |a Farnan, John |e verfasserin |4 aut | |
| 700 | 1 | |a Black, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Blighe, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Nesbit, M Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a McLaughlin, James A D |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Tara |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 40(2022), 18 vom: 20. Apr., Seite 2535-2539 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:18 |g day:20 |g month:04 |g pages:2535-2539 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2022.02.087 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 18 |b 20 |c 04 |h 2535-2539 | ||